The impact of expressions of treatment efficacy and out-of-pocket expenses on patient and physician interest in osteoporosis treatment: Implications for pay-for-performance programs

Journal of General Internal Medicine

Volumn 23, Issue 2, 2008, Pages 164-168

  Sinsky, Christine A ^a   Foreman Hoffman, Valerie ^b,c   Cram, Peter ^b  

^a Med Associates Clinic   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Osteoporosis treatment; Out of pocket expenses; Pay for performance programs; Treatment efficacy

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

ADULT; AGE DISTRIBUTION; ARTICLE; CONTROLLED STUDY; DRUG COST; DRUG EFFICACY; FEMALE; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH SURVEY; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PROTON NUCLEAR MAGNETIC RESONANCE; RISK REDUCTION; SEX RATIO;

ADULT; CLINICAL AUDIT; CROSS-SECTIONAL STUDIES; DEDUCTIBLES AND COINSURANCE; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HEALTH EXPENDITURES; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; PATIENT COMPLIANCE; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; REIMBURSEMENT, INCENTIVE; RISK; TREATMENT OUTCOME;

EID: 39149132077     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-007-0490-z     Document Type: Article

References (24)

1. Dudley RA. Pay-for-performance research: how to learn what clinicians and policy makers need to know. JAMA. 2005;294:1821-3.
2. Rosenthal MB, Frank RG, Li Z, Epstein AM. Early experience with pay-for-performance: from concept to practice. JAMA. 2005;294:1788-93.
3. Levin-Scherz J, DeVita N, Timbie J. Impact of pay-for-performance contracts and network registry on diabetes and asthma HEDIS measures in an integrated delivery network. Med Care Res Rev. 2006;63:14S-28S.
4. Milgate K, Cheng SB. Pay-for-performance: the MedPAC perspective. Health Aff. 2006;25:413-9.
5. Bodenheimer T, May JH, Berenson RA, Coughlan J. Can money buy quality? Physician response to pay for performance. Issue Brief Cent Stud Health Syst Change. 2005;(102)1-4.
6. U.S. Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: U.S. Department of Health and Human Services, Office of the Surgeon General; 2004.
7. Ray NF, Chan JK, Thamer M, Melton LJ. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res. 1997;12:24-35.
8. Brown JP, Josse RG, Scientific Advisory Council of the Osteoporosis Society of C. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ. 2002;167:S1-34.
9. U.S. Preventive Services Task Force. Screening for osteoporosis in postmenopausal women: recommendations and rationale. Ann Intern Med. 2002;137:526-28.
10. American Geriatrics Society Pay for Performance Proposal. Available at: http://www.americangeriatrics.org/policy/2006p4p_proposal.shtml. Accessed December 7, 2007.
11. CMS Physician Voluntary Reporting Program. Available at: http://www.cms.hhs.gov/apps/media/press/release.asp?Counter=1701. Accessed December 7, 2007.
12. Hodgson SF, Watts NB, Bilezikian JP, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract. 2003;9:544-64.
13. Gigerenzer G, Edwards A. Simple tools for understanding risks: from innumeracy to insight. Bmj. 2003;327:741-4.
14. Gigerenzer G. Why does framing influence judgment? J Gen Intern Med. 2003;18:960-1.
15. Malenka DJ, Baron JA, Johansen S, Wahrenberger JW, Ross JM. The framing effect of relative and absolute risk. J Gen Intern Med. 1993;8:543-8.
16. Nelson HD, Helfand M, Woolf SH, Allan JD. Screening for postmenopausal osteoporosis: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137:529-41.
17. Retail Pricing for Alendronate at Drugstore.com. Available at: http://www.drugstore.com/pharmacy/prices/drugprice.asp?ndc=00006093682&trx= 1Z5006. Accessed June 14, 2006.
18. Ancker JS, Kaufman D. Rethinking health numeracy: a multidisciplinary literature review. J Am Med Inform Assoc. 2007;14:713-21.
19. Naylor CD, Chen E, Strauss B. Measured enthusiasm: does the method of reporting trial results alter perceptions of therapeutic effectiveness? Ann Intern Med. 1992;117:916-21.
20. Hux JE, Naylor CD. Communicating the benefits of chronic preventive therapy: does the format of efficacy data determine patients' acceptance of treatment? Med Decis Making. 1995;15:152-7.
21. Halvorsen PA, Selmer, Kristiansen IS. Different ways to describe the benefits of risk-reducing treatments: a randomized trial. Ann Intern Med. 2007;146:848-56.
22. Forrow L, Taylor WC, Arnold RM. Absolutely relative: how research results are summarized can affect treatment decisions. Am J Med. 1992;92:121-4.
23. Laupacis A, Sackett DL, Roberts RS. Therapeutic priorities of Canadian internists. CMAJ. 1990;142:329-33.
24. Krumholz HM. Guideline recommendations and results: the importance of the linkage. Ann Intern Med. 2007;147:342-3.